IOMI

[sebfr]

Hi,

A Buy strategy...

News :
Iomai Chief Scientific Officer Dr. Gregory Glenn to Speak on Promising Developments in Vaccines at Cambridge Healthtech Institute Conference Today
Last Update: 8:01 AM ET Aug 22, 2006

Iomai Launches Phase 2 Clinical Study of Vaccine Patch for Travelers' Diarrhea
Company Enrolling Students in Field Study of Novel, Skin-Patch-Based Vaccine for Common Bacterial Illness
Last Update: 8:03 AM ET Aug 15, 2006

Iomai Announces Second Quarter 2006 Financial Results and Business Progress
Conference Call at 11 a.m. Eastern Time Today
Last Update: 8:57 AM ET Aug 14, 2006

Technical analysis :
1. IOMI has begun an uptrend
2. High volume on gap of breakout
3. Trendline breakout
4. Candelstick : Three rising methods pattern is in place..

Target :
1. Theoric target at 5.80
2. Fibonacci ratio with Support/Resistance : 4.81 and 5.43

Strategy :
1. Aggressive : buy now
2. Conservative : waiting for 4.29 resistance..

Stop loss :
1. Gap of breakout at 3.60-3.7
2. Support at 3.80

I hope IOMI will increase.. What do you think ?

[wrangler]

Check out insider buying
http://tinyurl.com/yfebcb

[BigSully1]

Anyone still following this?

IOMI up on good news +50X volume;

http://biz.yahoo.com/prnews/070117/sfw067.html?.v=89

[Draak]

Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers' Diarrhea Patch Vaccine
Thursday August 9, 8:30 am ET


GAITHERSBURG, Md., Aug. 9 /PRNewswire-FirstCall/ -- Iomai Corporation (Nasdaq: IOMI - News) today announced that interim results from a Phase 1 safety and immunogenicity trial of its patch-based vaccine for travelers' diarrhea found that all subjects who received the vaccine -- 19 elderly and 17 adult participants -- mounted an immune response, demonstrating that even elderly subjects with weaker immune systems respond to the vaccine.
ADVERTISEMENT


The trial was designed to compare the number of elderly subjects (65 and older) who seroconverted -- developed antibodies to the vaccine's active ingredient -- with the number of adult participants (aged 18 to 40) who seroconverted. Because the immune system is often less powerful in older people, many vaccines do not work as well in the elderly. However, all subjects who received the Iomai patch, regardless of age, seroconverted with IgG antibodies. Moreover, 18 of 19 elderly subjects and 15 of 17 adult subjects also seroconverted with IgA antibodies. The study was conducted in Belfast, Ireland, and subjects received two patches, 21 days apart, containing "heat labile" toxin, or LT, and were followed for 42 days. No treatment- related serious adverse effects were reported.

"The results of this trial further confirm that we can effectively deliver the active ingredient in our patch-based vaccine for travelers' diarrhea to adults of all ages, and based on this data, the Iomai travelers' diarrhea vaccine could be expected to extend coverage to this important at-risk segment of the traveling population," said Gregory M. Glenn, M.D., senior vice president and chief scientific officer of Iomai. "These results, coupled with the remarkable findings from our field study that we announced last week, provide additional evidence of the significant potential for Iomai's transcutaneous immunization (TCI) approach."

Iomai last week announced that a Phase 2 field trial of the vaccine found that healthy adults who traveled to Guatemala and Mexico and were vaccinated with the Iomai patch were 75 percent less likely to suffer moderate or severe travelers' diarrhea. With the high seroconversion rates in the elderly, the interim results from this new study suggest that the protective effect of Iomai's travelers' diarrhea vaccine may apply to all adults, not just young adults. Iomai will look to confirm this in its Phase 3 trials for its travelers' diarrhea vaccine, which the company intends to launch in 2008.

The study was designed to evaluate the safety of the travelers' diarrhea vaccine patch in the elderly and it met this primary endpoint. The secondary objective included evaluation of immunogenicity of the vaccine in the elderly compared with young adults. Iomai plans to submit the study data from the trial for publication as soon as possible.

ABOUT TRAVELERS' DIARRHEA

This year, approximately 55 million international travelers will visit countries where bacteria that cause travelers' diarrhea are endemic, particularly Africa, Asia and Latin America, and about 20 million of those travelers will develop travelers' diarrhea.

ETEC, the most common cause of travelers' diarrhea, represents just under half of all cases of travelers' diarrhea for international travelers to areas where ETEC is common. A recently completed market study suggested that there is a large market for an effective ETEC vaccine, potentially exceeding $500 million annually. If approved, the Iomai vaccine would be the first vaccine for travelers' diarrhea available in the United States.

ETEC's impact goes beyond travelers. The World Health Organization estimates that children in the developing world suffer 210 million episodes of diarrhea caused by ETEC annually, causing 380,000 deaths each year.

ABOUT IOMAI CORPORATION

Iomai Corporation discovers and develops vaccines and immune system stimulants, delivered via a novel, needle-free technology called transcutaneous immunization (TCI). TCI, discovered by researchers at the Walter Reed Army Institute of Research, taps into the unique benefits of a major group of antigen-presenting cells found in the outer layers of the skin (Langerhans cells) to generate an enhanced immune response. Iomai is leveraging TCI to enhance the efficacy of existing vaccines, develop new vaccines that are viable only through transcutaneous administration and expand the global vaccine market. Iomai currently has four product candidates in development: three targeting influenza and pandemic flu and one to prevent travelers' diarrhea. For more information on Iomai, please visit www.iomai.com.

[Draak]

September 17, 2007 - 11:49 AM EST


Rodman & Renshaw, LLC Announces Investment Opinion: Rodman & Renshaw, LLC Initiates Coverage of Iomai Corporation With A Market Outperform Rating
Analyst Sets 12 Month Target Price of $4.25

Rodman & Renshaw, LLC initiated research coverage of Iomai Corporation (NASDAQ:IOMI) with a Market Outperform Rating and a 12-month price target $4.25. Navdeep Jaikaria, PH.D, Senior Biotechnology Analyst, issued the report.

About Rodman & Renshaw, LLC

Rodman & Renshaw is a privately held, full-service investment bank committed to fostering the long-term success of growth companies through capital raising, strategic advice, insightful research, and the development of institutional support. More information is available at www.rodmanandrenshaw.com.

None of the research analysts or the research analyst's household has a financial interest in the securities of Iomai Corporation (including, without limitation, any option, right, warrant, future, long or short position).

As of August 31, 2007, neither Rodman & Renshaw, LLC nor its affiliates beneficially own 1% or more of any class of common equity securities of Iomai Corporation.

Neither the research analyst nor Rodman & Renshaw, LLC has any material conflict of interest with Iomai Corporation, of which the research analyst knows or has reason to know at the time of publication of this research report.

Rodman & Renshaw, LLC or its affiliates did not receive compensation from Iomai Corporation for investment banking services within the last twelve months but Rodman & Renshaw, LLC intends to seek compensation from Iomai Corporation for investment banking services within three months, following publication of the research report.

Neither the research analyst nor any member of the research analyst's household nor Rodman & Renshaw, LLC serves as an officer, director or advisory board member of Iomai Corporation.

Rodman & Renshaw, LLC does not make a market in Iomai Corporation securities as of the date of the research report.

The above information is not intended to be used as a primary basis of investment decisions. It is not a representation by Rodman & Renshaw, LLC or an offer or the solicitation of an offer to buy any security. Before investing in Iomai Corporation, you should carefully consider your risk tolerance and financial objectives.


Rodman & Renshaw, LLC, New York
William A. Iommi, Chief Compliance Officer, 212-356-0549
f: 212-201-8055

[Draak]

Iomai Patch-Based Vaccine Cut Rate of Travelers' Diarrhea by 75 Percent in Phase 2 Field Study
Statistically Significant Data Detailed at a Late-Breaking Presentation at ICAAC Meeting
CHICAGO and GAITHERSBURG, Md., Sept. 18 /PRNewswire-FirstCall/ -- Iomai Corporation (Nasdaq: IOMI) today announced that travelers who received the company's patch-based travelers' diarrhea vaccine were significantly less likely to be sickened as compared with travelers who receive a placebo, according to research presented today by Chief Scientific Officer Gregory Glenn, M.D. at a late-breaker presentation during the 'Vaccines and Pediatric Infections' session of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy being held in Chicago.

'We have demonstrated that vaccinated travelers can dramatically cut their risk of diarrhea by using our needle-free patch,' said Dr. Glenn, Iomai's founder. 'Those who received the Iomai vaccination were much less likely to get sick, and those who were sickened had far milder illness than those who received a placebo. These are clinically significant results that suggest that the patch vaccine will address the most significant unmet need for travel medicine: prophylaxis for travelers' diarrhea.'

The study found that of the 59 individuals who received the novel, patch-based vaccine, only three suffered moderate or severe diarrhea, while 23 of the 111 who received a placebo suffered moderate or severe diarrhea, a 75 percent reduction (p=0.007). One of the 59 volunteers in the vaccine group reported severe diarrhea, compared with 12 of the 111 in the placebo group, an 84 percent reduction (p=0.033).

'The results presented at ICAAC are the most robust ever shown in the prevention of travelers' diarrhea, and they suggest we may be near a turning point in the prevention of this common, often-serious disease,' said Herbert L. DuPont, M.D., professor and director of the Center for Infectious Diseases at The University of Texas School of Public Health and the principal investigator on the trial. 'If Phase 3 trials for the vaccine validate these results, those of us in travel medicine will have an excellent new weapon in our arsenal.'

The research was conducted in collaboration with researchers from the Johns Hopkins Bloomberg School of Public Health and the University of Texas School of Public Health.

Iomai plans to begin a Phase 3 program for the needle-free vaccine patch vaccine in 2008.

'We are moving this product ahead as quickly as possible,' said Chief Executive Officer Stanley C. Erck. 'This is a pressing, unmet medical need. Travelers' diarrhea is the most common travel ailment in the world, yet there are no effective vaccines available for the condition. A recently completed market study suggests that there is a $750 million market for effective protection against travelers' diarrhea, an opportunity that we are well-positioned to target.'

[setravis]

Shares of Iomai Surge on Agreement to
be Acquired by Intercell for US$6.60 Per/Share
Shares of Iomai Corporation (IOMI) more than doubled in early trading
after the Company announced an agreement to be acquired by Intercell
AG for US$6.60 per share, representing a fully diluted equity value of
approximately US$189 million. Certain of Iomai's largest shareholders,
together representing approximately 41 percent of Iomai's outstanding
common stock, have agreed to exchange their shares for Intercell stock
at an exchange ratio corresponding to a value of USD 6.60 per share of
Iomai common stock upon closing. Shareholders holding over 50 percent
of Iomai's total shares outstanding have entered into agreements
to vote in favor of the combination. Intercell will gain full rights to Iomai's
late stage Travelers' Diarrhea vaccine which is based on Iomai's proprietary
needle-free patch delivery vaccine technology and has shown
positive interim Phase II efficacy data. If approved, the medical use of
Iomai's Travelers' Diarrhea vaccine will be highly complementary with
Intercell's Japanese Encephalitis vaccine for which a Biologics License
Application was successfully submitted to the U.S. FDA in December
2007, and for which Intercell expects market approvals in the US, Europe
and Australia in 2008. Together, both vaccines create an extremely
attractive Traveler's Vaccine franchise which will target a combined
market opportunity of over US$1 billion in sales per year. Stanley C.
Erck, President and CEO of Iomai, said is a conference call today, "We
believe this transaction is in the best interest of all parties, including
shareholders, employees and ultimately patients. Together, we have
the potential to create a unique Travelers' Diarrhea vaccine franchise.
We also have other complimentary programs." He added, "Intercell also
has an excellent financial base that will insure the robust continued development
of our technology."